We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit Therapeutics to Report Financial Results for the Second Quarter
and Half Year Ended 31 July 2018 on 20 September 2018
Oxford, UK, and Cambridge, MA, US, 14 September 2018 - Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism
antibiotic innovation, will announce its financial results for the
second quarter and half year ended 31 July 2018 on 20 September 2018.
Summit will host a conference call the same day at 1:00pm BST / 8:00am
EDT. Conference call information will be included in the second quarter
and half year results press release, and a replay of the call will also
be available through the Company's website,
https://www.globenewswire.com/Tracker?data=YiC3mqbAGYWY9a91afF2eeuwffRSgLLysMp7aj83EW8l2ROVHYA0kYpux3P97rDPhe4W7XKN-ZmKYLia-klbif2euYu-YhaxgV0TVHq_EQc=
www.summitplc.com.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / mailto:summit@consilium-comms.com
summit@consilium-comms.com
---------------------------------
Lindsey Neville
-END-
(END) Dow Jones Newswires
September 14, 2018 07:00 ET (11:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
